Currently out of the existing stock ratings of Anupam Rama, 263 are a BUY (73.88%), 66 are a HOLD (18.54%), 27 are a SELL (7.58%).

Anupam Rama

Work Performance Price Targets & Ratings Chart

Analyst Anupam Rama, currently employed at JPMORGAN, carries an average stock price target met ratio of 40.46% that have a potential upside of 33.81% achieved within 173 days.

Anupam Rama’s has documented 692 price targets and ratings displayed on 58 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ORIC, Oric Pharmaceuticals at 06-Feb-2025.

Wall Street Analyst Anupam Rama

Analyst best performing recommendations are on VERA (VERA THERAPEUTICS).
The best stock recommendation documented was for VERA (VERA THERAPEUTICS) at 1/22/2024. The price target of $25 was fulfilled within 3 days with a profit of $8.7 (53.37%) receiving and performance score of 177.91.

Average potential price target upside

of $52.28 (43.66%) on ALXN (ALEXION PHARMACEUTICALS).
of $33.32 (51.57%) on MYOK (MYOKARDIA).
of $27.57 (91.07%) on APLS (APELLIS PHARMACEUTICALS).

AGIO Agios Pharm ALNY Alnylam Pharmaceuticals ALVR Allovir ALXN Alexion Pharmaceuticals ANAB AnaptysBio APLS Apellis Pharmaceuticals ATRA Atara Biotherapeutics BBIO BridgeBio Pharma BCAB Bioatla CCXI ChemoCentryx CNST Constellation Pharmaceuticals DVAX Dynavax Technologies EIDX Eidos Therapeutics FOLD Amicus Therapeutics FREQ Frequency Therapeutics GTHX G1 Therapeutics INFI Infinity Pharmaceuticals MRTX Mirati Ther MYOK MyoKardia NBIX Neurocrine Biosciences ORTX Orchard Therapeutics PLC OTIC Otonomy OYST Oyster Point Pharma PASG Passage Bio PTGX Protagonist Therapeutics RIGL Rigel Pharmaceuticals SRPT Sarepta Therapeutics SWTX SpringWorks Therapeutics TBPH Theravance Biopharma VIR Vir Biotechnology ZLAB Zai Lab Ltd CTMX CytomX Therapeutics GBIO Generation Bio Co IRWD Ironwood Pharmaceuticals KNSA Kiniksa Pharmaceuticals Ltd KOD Kodiak Sciences ELEV Elevation Oncology PTCT PTC Therapeutics CYTK Cytokinetics LJPC La Jolla Pharmaceutical Co RAPT RAPT Therapeutics VERA Vera Therapeutics CYT Cyteir Therapeutics ORIC Oric Pharmaceuticals REPL Replimune Group SLDB Solid Biosciences LLC SNDX Syndax Pharmaceuticals AGLE Aeglea Bio Therapeutics ANNX Annexon IDYA Ideaya Biosciences RARE Ultragenyx NUVL Nuvalent RLYB Rallybio Corp OLMA Olema Pharmaceuticals SAGE Sage Therapeutic COGT Cogent Biosciences DAWN Day One Biopharmaceuticals TVTX Travere Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Gregory Renza (RBC)